Tafenoquine in Severe Babesiosis: First Prospective Data in a Field With No Approved Therapy, But Relapse Risk Looms

60 Degrees Pharma to Release Interim Babesiosis Study Data

60 Degrees Pharmaceuticals announced it will release interim analysis results on October 6, 2026, from its clinical study (NCT06207370) evaluating tafenoquine in patients hospitalized with severe babesiosis. Concurrently, the company will host a Key Opinion Leader (KOL) investor webinar featuring Dr. Peter Krause and Dr. Edouard Vannier to discuss the unmet medical need for babesiosis treatments and tafenoquine's potential role in addressing recurrent tick-borne infections.

• On October 6, 2026, 60 Degrees Pharmaceuticals will disclose interim analysis results for its tafenoquine study in severe babesiosis. This will be followed by a KOL investor webinar at 11:00 a.m. ET, where experts will review clinical data and literature, and discuss tafenoquine's potential for recurrent tick-borne infections.
• The webinar will feature Dr. Peter Krause, a leading authority on human babesiosis, and Dr. Edouard Vannier, a specialist in Babesia microti infection. They will address the clinical burden of persistent babesiosis in immunocompromised hosts, current treatment limitations, and the mechanistic rationale for tafenoquine combination therapy, highlighting the significant unmet medical need.
• Currently, there is no FDA-approved treatment or vaccine for babesiosis, and tafenoquine is not yet approved for this indication. Tafenoquine is, however, approved by the FDA for malaria prophylaxis in the United States under the product name ARAKODA® and is sold commercially in the U.S. and Australia.

Addressing the Unmet Needs in Severe Babesiosis Treatment

Severe babesiosis presents a constellation of treatment challenges that are particularly pronounced in immunocompromised hosts, where standard regimens frequently prove insufficient. The limitations of current approaches span drug resistance, treatment duration, and the absence of validated salvage therapies.

• Emergence of drug resistance: Babesia microti can develop resistance to azithromycin-atovaquone during treatment in highly immunocompromised patients. Three such cases were described in which a subcurative course of azithromycin-atovaquone was associated with the eventual development of resistance to this drug regimen, with one patient dying of complications related to babesiosis.

• Persistent and relapsing infection in immunocompromised hosts: Immunocompromised patients — particularly those with B cell lymphoma, asplenia, or prior rituximab exposure — are at risk of persistent relapsing illness. Such patients generally require antibabesial treatment for ≥6 weeks to achieve cure, including 2 weeks after parasites are no longer detected on blood smear, and may require 2–10 courses of therapy before resolution.

• Suboptimal standard regimens for high-risk populations: Most cases of human babesiosis are successfully treated with atovaquone and azithromycin or clindamycin and quinine, but severe disease may require prolonged treatment, and the optimal therapy for highly immunocompromised patients remains undetermined.

• Limited and investigational salvage options: Tafenoquine, approved for malaria indications, has been explored as an adjunct for relapsing babesiosis caused by B. microti. A lower weekly maintenance dose of 200 mg was associated with delayed clearance, and in one case tafenoquine administered alone failed to prevent relapse, underscoring that its role remains incompletely defined. Clofazimine has shown activity against B. microti in severely immunocompromised murine models — including against atovaquone-resistant strains — but additional preclinical studies are required to identify the minimal dose and dosage for babesiosis.

• Cytochrome b resistance mutations and fitness trade-offs: A mutation in the B. microti mitochondrial cytochrome b gene that confers resistance to antibabesial drugs does not affect parasite fitness during the mammalian blood phase and is genetically stable as parasite burden increases, meaning resistant parasites can persist and propagate in the host without fitness penalty.

Current Treatment Approaches for Severe Babesiosis

Severe babesiosis is managed with a combination of antimicrobial therapy and, in high-parasitemia cases, adjunctive red blood cell exchange (RCE) transfusion. Antimicrobial regimens documented in clinical practice include azithromycin plus atovaquone, as well as clindamycin combined with quinine or quinidine. Treatment duration varies considerably by host immune status: in immunocompromised or asplenic patients (ICAH), the median treatment duration is 27 days compared to 10 days in immune-intact patients, extending to a median of 43 days in those with both immunocompromising conditions and asplenia/hyposplenia.

RCE is employed as an adjunct to antimicrobial therapy in cases characterized by high parasitemia and evidence of end-organ dysfunction. Available data suggest that parasitemia exceeding 10%, coupled with clinical status, serves as a reasonable indicator for RCE. In a case series of 19 patients, RCE reduced mean parasitemia from 12.9% to 3.4% — a mean percent reduction of 75% — and was performed on average 1.3 days after presentation. Preprocedural parasitemia and age were significant predictors of post-procedural hospital length of stay, while reduction in parasitemia level did not correlate with post-RCE length of stay. Reduction in parasitemia level is described as the only known benefit of RCE in severe babesiosis. RCE has also been reported as a potentially safe treatment option in severe babesiosis during pregnancy when antimicrobial therapy alone is ineffective or poorly tolerated.

In immunocompromised hosts, disease severity is substantially greater, with higher rates of acute kidney injury (24% vs. 11%), acute respiratory distress syndrome (11% vs. 4%), and greater need for packed red blood cell transfusion (31% vs. 17%) and exchange transfusion (18% vs. 6%) compared to immune-intact patients. Hematologic malignancy (OR=7.0) and B-cell-depleting therapies (OR=9.4) are significant predictors of recurrence. Despite widespread use of follow-up blood smears and PCR testing, these modalities did not reliably predict recurrence, underscoring the need for more effective monitoring strategies in high-risk populations.

Tafenoquine's Potential to Reshape Severe Babesiosis Treatment

Babesiosis, a tick-borne parasitic infection, poses a growing threat, particularly to immunocompromised individuals where it can lead to severe, relapsing, and even fatal outcomes. The current therapeutic landscape is complicated by the emergence of drug resistance, notably to atovaquone, highlighting a significant unmet medical need for more effective and durable treatments. Against this backdrop, the upcoming release of interim human clinical trial data for tafenoquine in severe babesiosis marks a crucial moment for the field.

Tafenoquine, an 8-aminoquinoline with a history in malaria treatment, has shown considerable promise in preclinical studies. Research indicates its broad activity against various 'Babesia' species, including those that have developed resistance to existing drugs. In animal models, tafenoquine has demonstrated rapid clearance of parasites, and importantly, combinations with agents like atovaquone have achieved radical cure and even conferred protective immunity. This suggests tafenoquine could not only treat acute infections but also potentially prevent recurrence, a major challenge in vulnerable patient populations.

Strategically, a positive outcome from these interim results could position tafenoquine as a pivotal new agent, potentially establishing a new standard of care for severe and relapsing babesiosis. This would represent a successful repurposing of an existing drug, leveraging its known profile to address a distinct and critical medical need. However, several considerations remain paramount. While preclinical data are encouraging, the interim human data must unequivocally demonstrate robust efficacy in the complex clinical setting of severe babesiosis, especially given the observed need for combination therapy or repeated dosing in some animal models to prevent relapse. Furthermore, tafenoquine's established safety profile, including the risk of hyperkalemia and the need to screen for glucose-6-phosphate dehydrogenase deficiency, will require careful management in this patient population. The long-term potential for 'Babesia' to develop resistance to tafenoquine itself also warrants ongoing vigilance. Nevertheless, if these interim results are favorable, tafenoquine could offer a much-needed therapeutic advance, significantly improving outcomes for patients battling this challenging infection.